New drug shows promise for reducing narcolepsy attacks in long-term trial
NCT ID NCT05113745
First seen Nov 14, 2025 · Last updated Apr 28, 2026 · Updated 26 times
Summary
This study looked at the long-term safety and effectiveness of a drug called AXS-12 for people with narcolepsy who also have cataplexy (sudden muscle weakness) and excessive daytime sleepiness. The 68 participants had already completed an earlier study and continued taking AXS-12. Researchers tracked side effects and measured how much cataplexy attacks decreased over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Research Site
Phoenix, Arizona, 85054, United States
-
Clinical Research Site
Boulder, Colorado, 80301, United States
-
Clinical Research Site
Colorado Springs, Colorado, 80918, United States
-
Clinical Research Site
Brandon, Florida, 33511, United States
-
Clinical Research Site
Clearwater, Florida, 33765, United States
-
Clinical Research Site
Doral, Florida, 33122, United States
-
Clinical Research Site
Miami Lakes, Florida, 33016, United States
-
Clinical Research Site
Winter Park, Florida, 32789, United States
-
Clinical Research Site
Atlanta, Georgia, 30315, United States
-
Clinical Research Site
Atlanta, Georgia, 30328, United States
-
Clinical Research Site
Stockbridge, Georgia, 30281, United States
-
Clinical Research Site
Chevy Chase, Maryland, 20815, United States
-
Clinical Research Site
Kalamazoo, Michigan, 49008, United States
-
Clinical Research Site
Novi, Michigan, 48377, United States
-
Clinical Research Site
Neptune City, New Jersey, 07753, United States
-
Clinical Research Site
Denver, North Carolina, 28037, United States
-
Clinical Research Site
Gastonia, North Carolina, 28054, United States
-
Clinical Research Site
Huntersville, North Carolina, 28078, United States
-
Clinical Research Site
Cincinnati, Ohio, 45245, United States
-
Clinical Research Site
Wyomissing, Pennsylvania, 19610, United States
-
Clinical Research Site
Charleston, South Carolina, 29425, United States
-
Clinical Research Site
Columbia, South Carolina, 29201, United States
-
Clinical Research Site
Austin, Texas, 78731, United States
-
Clinical Research Site
San Antonio, Texas, 78229, United States
-
Clinical Research Site
Toronto, Ontario, M5S 3A3, Canada
Conditions
Explore the condition pages connected to this study.